Jun 30, 2026
A federal ethics filing shows an account in President Donald Trump's name bought between $1 million and $5 million of Axon Enterprise (NASDAQ:AXON) stock on Feb. 10, 2026. Fourteen days later, U.S. Immigration and Customs Enforcement posted a notice seeking a five-year, $220 million contract for stun guns, and the specifications it laid out point to one company's product line.
No charges have been filed, and no insider trading has been proven. The contract hasn't been awarded, and there's no evidence Trump knew about the procurement or that Axon knew about the purchase. But the timing is the latest entry in a pattern that has dogged the president since his first-quarter trading disclosures landed in May: an account in his name buying into a company shortly before his administration takes an action that benefits it.
What ICE's $220 million Taser contract covers
At its core, this is an equipment refresh. ICE's Office of Firearms and Tactical Programs currently fields about 4,300 conductive energy weapons — the X26P/X2 models, roughly four years old. The agency wants to replace and expand that inventory to about 17,800 devices over five years, bundling warranty, training cartridges and instructor certification into one contract to control lifecycle costs.
Thanks for subscribing!
Read the best of Moneywise in 5 minutes or less.
By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.
Agencies refresh duty weapons on cycles like this routinely. Axon is also the incumbent: it holds ICE's current T10 contract, worth about $16.1 million and set to expire Aug. 21, 2026. A sources-sought notice in February for a contract lapsing in August is ordinary procurement timing. On its own, the procurement is unremarkable.
Must Read
- The ultra-rich use these 5 real estate strategies to build wealth while they sleep — you can start with just $100
- Here’s the average income of Americans by age in 2026. Are you keeping up or falling behind?
- Insurance companies profit most from drivers who auto-renew without shopping around. Comparing 100+ quotes takes 2 minutes and costs nothing
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Why the ICE contract specs point to Axon
The Feb. 24 notice — a Sources Sought Notice and Request for Information, not a formal solicitation — carries an estimated value of $220 million and describes a firm-fixed-price contract with a one-year base period and four one-year options.
Advertisement
The attached Statement of Work doesn't ask for a generic stun gun. It names the target: an upgrade to "the T10 CEW," with a 10-probe cartridge and a 45-foot probe standoff distance, replacing the older 25-foot X26P/X2 units. The TASER 10 is an Axon product. Axon makes roughly 90% of U.S. conductive energy weapons, according to Brown Advisory.
The notice never says "Axon" by name. But procurement reviewers and policing experts who examined the requirements told CNBC the specifications align with Axon's models and would effectively exclude any rival bidder. A refresh that could, in principle, be completed across vendors is instead written around a single manufacturer's current flagship. That functionally routes the $220 million to one company.
Trump's Axon stock purchase and the trades around it
According to the periodic transaction report filed with the U.S. Office of Government Ethics on May 8, the Feb. 10 Axon purchase falls in the $1 million-to-$5 million band, one of the larger single positions in a quarter that saw thousands of transactions.
The picture isn't one-directional. The same filing records smaller Axon trades running both ways through the quarter — additional purchases in March and several sales in February and March, none larger than $100,000. That two-way activity is the foundation of the White House's defense: a broad, actively managed portfolio rather than a single targeted bet. Still, the asymmetry is hard to miss. The Feb. 10 buy is an order of magnitude larger than the other Axon trades, and it lands two weeks before the notice posts.
What the White House says about Trump's Axon trades
The Trump Organization says the president's holdings sit in fully discretionary accounts managed by third-party financial institutions, and that Trump and his family don't direct, select or approve specific investments. White House spokesperson Anna Kelly told CNBC there are "no conflicts of interest," calling the scrutiny "the same, tired narrative that Democrats have pushed against President Trump, his family, and his administration for a decade." She said the president "only acts in the best interests of the American public."
Eric Trump, one of the trustees, has said any suggestion that individual stocks are bought or sold "at the discretion of any member of the Trump family, would be a lie and blatantly false."
Two caveats sit alongside those statements. The filings don't specify who placed the trades. And ethics specialists note the arrangement isn't a true blind trust: every president from Richard Nixon through Barack Obama used a structure that put assets fully out of the holder's control, and Trump didn't divest or set one up. Presidents are also exempt from the criminal conflict-of-interest statute that binds other executive-branch officials, which is why this is an ethics-and-appearance question rather than, on current facts, a legal one.
Where the ICE Axon contract stands now
Nothing has been awarded. Because the notice was an RFI rather than a solicitation, there's no public record of which vendors responded, or whether any did. CNBC reported the award appears stalled, slowed by the price tag and a leadership shake-up at the Department of Homeland Security.
Advertisement
ICE posted the notice about a week before then-Secretary Kristi Noem was fired, and before she had signed off on it. A person familiar with the procurement said DHS is expected to keep pursuing it, but the timeline is unclear.
Trump's other well-timed stock buys: Dell
The Axon sequence isn't isolated. When Trump's first-quarter disclosures became public in May, reporting flagged the same shape across several holdings. An account in his name bought $1 million to $5 million of Dell (NYSE:DELL) on the same Feb. 10. Nine days later he urged Americans to "go out and buy a Dell," and repeated the praise at a White House event in May. Dell later landed a $9.7 billion Pentagon contract, and the stock is up roughly 255% since his first endorsement. The Dell family had separately pledged $6.25 billion to the administration's "Trump Accounts" program in December.
The volume itself drew scrutiny. The OGE filings logged more than 3,700 transactions in the quarter, more than 40 per market day, worth a cumulative $220 million to $750 million. The trading prompted CNBC's Jim Cramer to go briefly silent on air when a co-host raised it. Trump, who has repeatedly accused Nancy Pelosi of profiting on inside information, disclosed a quarter of trading that dwarfs her three-year volume, and was fined $200 for filing some trades late.
What the Axon news means for Axon investors
For Axon shareholders, the durable question is the company's heavy reliance on government budgets. The potential ICE award would land as Axon posts record demand: revenue hit $807.3 million in the first quarter of 2026, up 34% from a year earlier. Executives have called DHS contracts a "major opportunity," and the company has staffed up to chase it, rebuilding its federal team and hiring a longtime Palantir executive. Axon also spent nearly $2.5 million on lobbying last year, its highest annual total.
That federal book comes with a catch the company flags itself. Axon's own filings cite dependence on public-sector spending and non-appropriation clauses that let agencies walk away from commitments. The current contract lapses Aug. 21 while the follow-on sits stalled, leaving part of that near-term federal revenue up in the air on timing.
The market's read has been volatile. Axon climbed more than 34% in the week after the February notice, but the stock is down roughly 25% so far this year. The appearance problem and the investment problem are separate. One is about how a refresh got written and when a stock got bought. The other is about how much of Axon's growth leans on contracts that, by the company's own admission, aren't guaranteed.
You May Also Like
- JP Morgan sees gold hitting $6,000/oz before 2027 — and a Gold IRA lets you hold the physical metal while deferring the tax bill. Get your free guide from Priority Gold
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and the simple steps to fix it ASAP
- Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
- Millionaires under 43 are reshaping investing — just 25% of their portfolios are in stocks. Here’s where their money is going
Rudro is an Editor with Moneywise. His work has appeared on Yahoo Finance, MSN, MSN Money, Apple News, Samsung News and the San Diego Union Tribune.
